- Imugene presents data at the American Society of Gene and Cell Therapy conference
- 4DMedical’s lung scanner gets licence to use at Harry S. Truman Memorial Veterans Hospital
Immuno-oncology biotech, Imugene (ASX:IMU), jumped almost 7% this morning after announcing that its onCARlytics technology was presented at the American Society of Gene and Cell Therapy’s annual meeting.
The data, presented as a poster presentation at the conferece held in Los Angeles, showed that onCARlytics, when combined with Eureka Therapeutics’ ARTEMIS cell receptor platform, demonstrated anti-tumour activity in vivo against hepatocellular carcinoma.
Hepatocellular carcinoma or HCC is the most common type of primary liver cancer, and sixth most common cancer worldwide.
It occurs most often in people with chronic liver diseases, such as cirrhosis caused by hepatitis B or hepatitis C infection, and currently there are few therapies available to treat it.
To date, CAR T cell therapies against HCC have shown nominal efficacy in clinical trials, and therefore more novel development of these therapies are needed.
4D Medical’s lung scanner granted for use at hospital
Meanwhile, 4DMedical (ASX:4DX) said that following the successful pilot of the first XV LVAS scan at Harry S. Truman Memorial Veterans Hospital (VA), the company has now been granted Authority to Operate (ATO) for the device at this site.
The XV Technology enables physicians to understand regional airflow in their patients’ lungs, and identify respiratory deficiencies earlier and with greater sensitivity as they breathe.
This first ATO is an important milestone for 4DX, as it demonstrates the robust and secure nature of the lung scanner platform.
Additionally, once 4DMedical has ATO at two sites, it is eligible to apply for a National ATO, which will provide the company with authorisation at all 171 major clinical centres within the VA network.
“I feel strongly that our XV Technology is the best way to provide every veteran with access to rich information on the effects of toxic exposures on their lungs, without the burden of an expensive and invasive biopsy,” said 4DX founder and CEO, Andreas Fouras.